InnoCan Pharma Receives Major Scientific Validation for Drug Delivery Platform

A significant milestone has been reached by InnoCan Pharma as newly published research provides third-party confirmation of its proprietary drug delivery technology's effectiveness. The company announced today that critical study results validating its liposomal platform technology (LPT) have appeared in the respected scientific publication Precision Nanomedicine following peer review.

The research demonstrates that a single subcutaneous injection can maintain therapeutic CBD plasma concentrations for an extended 28-day period. This finding represents a potential breakthrough in sustained drug delivery systems.

Conducted using Göttingen minipigs—a regulatory-recognized model known for accurately predicting human metabolic responses—the study provides essential data for future regulatory submissions. The experimental design evaluated both pharmacokinetic performance and crucial safety parameters, addressing key requirements for pharmaceutical development.

Key Advantages Revealed by Research

Market analysts highlight several breakthrough characteristics revealed in the published data that could substantially reduce development risks:

• Sustained drug release: Detectable CBD concentrations persisted throughout the entire 28-day observation period following a single administration
• Human applicability: Elevated blood levels of the metabolite 7-COOH-CBD indicate metabolic pathways consistent with expected human responses
• Strong safety profile: No systemic adverse effects were reported, with good local tolerance observed at injection sites

This independent verification of InnoCan's drug delivery platform represents what industry observers term a "de-risking event" that could build market confidence in the technology.

Should investors sell immediately? Or is it worth buying InnoCan Pharma?

Regulatory Pathway Gains Clarity

Beyond the scientific validation, InnoCan has secured additional momentum through confirmed alignment with the U.S. Food and Drug Administration regarding its preclinical development strategy. This regulatory clarity removes uncertainties commonly associated with novel drug delivery technologies.

The company now has an established framework for transitioning to human clinical trials. The 28-day sustained release profile strategically positions InnoCan in the pain management market, where current standards often require daily oral medications or frequent injections. This technology could effectively address patient compliance challenges while offering a non-opioid alternative for chronic pain management.

Investor Outreach Intensifies

With scientific validation achieved, focus now shifts to commercialization efforts. The company is accelerating its capital market strategy, confirming participation in the ThinkEquity Conference 2025. This signals coordinated initiatives to dramatically increase visibility among U.S. institutional investors.

The successful minipig data forms the foundation for an Investigational New Drug (IND) application, a mandatory requirement before human trials can commence. The combination of peer-reviewed scientific validation and regulatory alignment creates a favorable environment for advancing through subsequent development phases. Market participants now watch to see whether InnoCan can translate these technical achievements into sustained share price appreciation.